New Triple-Drug diabetes pill aims for better blood sugar control
NCT ID NCT07441187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new once-daily tablet that combines three diabetes drugs (henagliflozin, retagliptin, and metformin) in Chinese adults with type 2 diabetes. About 300 participants will take the pill for 24 weeks to see how well it lowers blood sugar and check for side effects. The goal is to find a more convenient and effective treatment option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an Anti-Inflammatory diet tame type 2 diabetes?
- New diabetes combo pill aims to beat single drugs in major trial
- New combo therapy aims to improve diabetes management
- New triple therapy aims to protect kidneys in diabetes patients
- New combo diabetes pill tested in healthy volunteers
- New diabetes pill put to the test: does food change how it works?